Zobrazeno 1 - 10 of 103 pro vyhledávání: '"M. Lichinitser"'
4
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
Autor: Andrew Strickland, G Manikhas, Jeremy Shapiro, Rakesh K. Jain, Niall C. Tebbutt, Marc Peeters, B Wu, M Lichinitser, W Rogowski, Attili Satya Suresh, X Huang, Douglas Warner
Publikováno v: The British journal of cancer
British Journal of Cancer
Background: This phase 2 study evaluated trebananib (AMG 386), an investigational peptide-Fc fusion protein that neutralises the interaction between angiopoietins-1/2 and the Tie2 receptor, plus FOLFIRI as second-line treatment for patients with meta
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8829540222271c22192877ec709f6818
https://hdl.handle.net/10067/1083020151162165141
Zobrazit plný text záznamu
7
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
Autor: Matti Aapro, H. Sleeboom, Christian Peschel, A. Macciocchi, J. Mezger, R. Gralla, M. Lichinitser, S. van der Vegt, Roberto Labianca, Giuseppe Tonini
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 14(10)
Background: Although all first-generation 5-HT3 receptor antagonists demonstrate efficacy in preventing acute chemotherapy-induced nausea and vomiting (CINV), effective prevention of delayed CINV has not yet been achieved. This study compared the eff
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46449a5753f9d0779d57fa9d8400e942
https://pubmed.ncbi.nlm.nih.gov/14504060
Zobrazit plný text záznamu
8
Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer
Autor: Per Eystein Lønning, Kathleen I. Pritchard, K. Wolter, Peter D. Eisenberg, Aman U. Buzdar, R. Chew, M. Alderdice, S. Yan, M. Lichinitser, K. Fly, Daniel F. Hayes, A. El-Khoudary, K. Burke, Adrian V. Lee, Geoffrey Falkson, R. Gopal, Allan Lipton
Publikováno v: Breast cancer research and treatment. 73(2)
This trial was designed to demonstrate equivalence between droloxifene 40 mg/d and tamoxifen 20 mg/d as first-line treatment in pre- and post-menopausal women with ER+ and/or PgR+ advanced breast cancer based on time to disease progression and tumor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3138ef8df9601cceb4fdf71410871af7
https://pubmed.ncbi.nlm.nih.gov/12088118
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje